| abstract |
The invention relates to the use of a peptidic sequence comprising consisting of a sequence extending to minimum of residuals: -275 to 366 (SEQ ID NO:4) and/or -367 to 455 (SEQ ID NO:6) and/or -456 to 531 (SEQ ID NO:8) of SEQ ID NO:10, and to maximum to a sequence corresponding to SEQ ID NO:10, for preparing a drug for preventing and treating angiogenesis -related diseases such as cancers, age-related macular retrogradation, retinopathy, psoriasis or rheumatoid arthritis. |